Treating the Elderly Patient with Acute Myelogenous Leukemia
Open Access
- 4 December 2010
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 62-69
Abstract
Decisions regarding the optimal treatment of acute myelogenous leukemia in the elderly patient requires the consideration of multiple factors. Population-based studies have demonstrated that, for all age groups, aggressive therapy results in improved survival and quality of life when compared with palliative care. The optimal induction and postremission regimen for older patients has yet to be determined. Furthermore, not all patients are candidates for such therapy. Consideration of patient and disease-related factors can help to determine the appropriateness of intensive therapy in a given patient. For those patients for whom aggressive induction therapy does not seem to be in their best interest, novel agents are being investigated that will hopefully address the issues of induction death and early relapse associated with these patient populations.Keywords
This publication has 47 references indexed in Scilit:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Outcomes and quality of care in acute myeloid leukemia over 40 yearsCancer, 2009
- Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern SwitzerlandTumori Journal, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow TransplantationHaematologica, 2009
- Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative GroupJournal of Clinical Oncology, 2009
- Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st centuryHaematologica, 2008
- Age and acute myeloid leukemiaBlood, 2006